Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G A Pietersz

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Drugs & Aging|August 25, 1999
Monoclonal antibody-directed cytotoxic therapy: potential in malignant diseases of agingC Panousis, G A Pietersz
Journal of Drug Targeting|January 1, 1994
Antibody-targeted drugs for the therapy of cancerG A Pietersz, K Krauer
Biotherapy (Dordrecht, Netherlands)|January 1, 1993
The comparative effects of IL-1 and TNF on AMN-anti-Ly 2.1 immunoconjugate therapyK G Krauer, G A Pietersz
Cancer Immunology, Immunotherapy : CII|August 1, 1994
Reduction in the toxicity of aminopterin--monoclonal-antibody conjugates by leucovorinA J Rowland, G A Pietersz
Immunology and Cell Biology|June 1, 1997
Tumour eradication with high-dose idarubicin-anti-Ly-2.1 with murine tumour necrosis factor-alpha in miceG A Pietersz, M Bogdanovski, W Li
Vaccine|February 13, 2001
A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathwayG A Pietersz, W Li, V Apostolopoulos
Immunology and Cell Biology|April 1, 1989
Intratumour therapy of solid tumours with ricin-antibody conjugatesJ Kanellos, I F McKenzie, G A Pietersz
Immunology and Cell Biology|October 1, 1996
Breast cancer immunotherapy: current status and future prospectsV Apostolopoulos, I F McKenzie, G A Pietersz
Vaccine|June 1, 1996
Cell-mediated immune responses to MUC1 fusion protein coupled to mannanV Apostolopoulos, G A Pietersz, I F McKenzie
Cellular and Molecular Life Sciences : CMLS|April 15, 2000
Generation of cellular immune responses to antigenic tumor peptidesG A Pietersz, V Apostolopoulos, I F McKenzie
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Drugs & Aging|August 25, 1999
Monoclonal antibody-directed cytotoxic therapy: potential in malignant diseases of agingC Panousis, G A Pietersz
Journal of Drug Targeting|January 1, 1994
Antibody-targeted drugs for the therapy of cancerG A Pietersz, K Krauer
Biotherapy (Dordrecht, Netherlands)|January 1, 1993
The comparative effects of IL-1 and TNF on AMN-anti-Ly 2.1 immunoconjugate therapyK G Krauer, G A Pietersz
Cancer Immunology, Immunotherapy : CII|August 1, 1994
Reduction in the toxicity of aminopterin--monoclonal-antibody conjugates by leucovorinA J Rowland, G A Pietersz
Immunology and Cell Biology|June 1, 1997
Tumour eradication with high-dose idarubicin-anti-Ly-2.1 with murine tumour necrosis factor-alpha in miceG A Pietersz, M Bogdanovski, W Li
Vaccine|February 13, 2001
A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathwayG A Pietersz, W Li, V Apostolopoulos
Immunology and Cell Biology|April 1, 1989
Intratumour therapy of solid tumours with ricin-antibody conjugatesJ Kanellos, I F McKenzie, G A Pietersz
Immunology and Cell Biology|October 1, 1996
Breast cancer immunotherapy: current status and future prospectsV Apostolopoulos, I F McKenzie, G A Pietersz
Vaccine|June 1, 1996
Cell-mediated immune responses to MUC1 fusion protein coupled to mannanV Apostolopoulos, G A Pietersz, I F McKenzie
Cellular and Molecular Life Sciences : CMLS|April 15, 2000
Generation of cellular immune responses to antigenic tumor peptidesG A Pietersz, V Apostolopoulos, I F McKenzie
Pageof 7